Company profile

Gliapharm SA

GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.

More news about Gliapharm SA

15.12.2023 09:00

GliaPharm secures $4.2 million to advance its lead program

Please login or
register to use the
awards follow feature
28.10.2022 15:00

GliaPharm and UCB enter drug discovery research collaboration

Please login or
register to use the
awards follow feature
04.07.2022 17:00

Transmutex, V-Labs, GliaPharm and Deasyl get FIF Funding

Please login or
register to use the
awards follow feature
28.02.2022 15:03

GliaPharm braces to enter the clinical phase

Please login or
register to use the
awards follow feature
26.05.2020 17:04

Geneva-based GliaPharm completes a CHF 2 million financing round

Please login or
register to use the
awards follow feature
14.01.2019 16:19

Six Swiss startups among the finalists of Hello tomorrow challenge

Please login or
register to use the
awards follow feature
06.08.2018 13:41

FIT grants CHF 400'000 to four new Western Switzerland startups

Please login or
register to use the
awards follow feature
Gliapharm SA

Founded
2016

Kanton
GE


LinkedIn

Homepage

rss